Vasopressin receptor antagonist

Vasopressin antagonists ( group of Vaptane ) are drugs which are for the treatment of heart failure, liver failure and the syndrome of inappropriate antidiuretic hormone secretion ( SIADH ) allowed. Vaptane are direct ADH antagonists that block the action of ADH ( vasopressin ) at the vasopressin V2 receptor subtype of the kidney. The incorporation of aquaporins in the walls of the header of the kidney is inhibited, and thus promote the excretion of electrolyte-free water.

Tolvaptan is the first and currently only available in Europe oral selective vasopressin V2 - receptor antagonist. Further, in-process materials are lixivaptan, Mozavaptan and Satavaptan (V2 - selective), and Relcovaptan ( V1A - selective).

Conivaptan is a Certified in the U.S. " dual " vasopressin antagonist that inhibits the vasopressin V1b receptors and V2.